E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers A > Headlines for AVI BioPharma, Inc. > News item
Published on 7/31/2009 in the Prospect News Convertibles Daily and Prospect News High Yield Daily.

AVI BioPharma files $125 million shelf for debt, preferreds, stock

New York, July 31 - AVI BioPharma, Inc. registered to sell up to $125 million of common stock, preferred stock, debt securities and warrants using an S-3 shelf filing with the Securities and Exchange Commission.

Securities may be issued as convertibles.

Proceeds will be used for research and development and for general corporate purposes.

AVI BioPharma is a Corvallis, Ore., biopharmaceutical company specializing in the discovery and development of RNA-based drugs.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.